Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871852 | 0.93 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2POLBKDM1AHDAC8 | |
| SCHEMBL5361729 | 0.91 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL4872655 | 0.88 | NR1H2 (0.37) | HSD17B10SMN1; SMN2POLBHDAC8MEN1 | |
| SCHEMBL6843843 | 0.88 | NR1H2 (0.37) | HSD17B10SMN1; SMN2POLBHDAC8MEN1 | |
| SCHEMBL5984320 | 0.87 | HDAC8 (0.38) | HSD17B10SMN1; SMN2POLBHDAC8MEN1 | |
| SCHEMBL10215476 | 0.81 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2POLBKDM1AMEN1 | |
| SCHEMBL2126924 | 0.81 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2POLBKDM1AMEN1 | |
| SCHEMBL31148270 | 0.81 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2POLBKDM1AMEN1 | |
| SCHEMBL18591178 | 0.80 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2POLBHDAC8EPHX2 | |
| SCHEMBL25930944 | 0.80 | HSD17B10 (0.39) | HSD17B10SMN1; SMN2POLBHDAC8EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814893-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006055070-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | NRDC, NISCH, CLSPN | HSD17B10 1253/4885SMN1; SMN2 3897/4885POLB 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.